RIVAROXABAN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Rivaroxaban Market, By Indication (Atrial Fibrillation, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Prophylaxis of Venous Thromboembolism (VTE), and Others), By Formulation (Tablets and Suspension), By Patient Type (Adults and Paediatrics), By Distribution Channel (Hospitals and Clinics, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In: 03 Apr, 2026
Code: CMI1962
Page number: 150
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range : 2020 - 2024
- Base Year : 2025
- Estimated Year : 2026
- Forecast Period : 2026-2033

Table of Contents (Version-2026)

RESEARCH OBJECTIVES AND ASSUMPTIONS
- Research Objectives
- Assumptions
- Abbreviations
MARKET PURVIEW
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Global Rivaroxaban Market, By Indication
  - Global Rivaroxaban Market, By Formulation
  - Global Rivaroxaban Market, By Patient Type
  - Global Rivaroxaban Market, By Distribution Channel
  - Global Rivaroxaban Market, By Region
MARKET DYNAMICS, REGULATIONS, AND TRENDS ANALYSIS
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
Global Rivaroxaban Market, By Indication, 2026 - 2033, (USD Mn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2022 - 2033
  - Segment Trends
- Atrial Fibrillation
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Deep Vein Thrombosis (DVT)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Pulmonary Embolism (PE)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Prophylaxis of Venous Thromboembolism (VTE)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others (Acute Coronary Syndrome, etc.)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Global Rivaroxaban Market, By Formulation, 2026 - 2033, (USD Mn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2021 - 2033
  - Segment Trends
- Tablets
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Suspension
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Global Rivaroxaban Market, By Patient Type, 2026 - 2033, (USD Mn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2021 - 2033
  - Segment Trends
- Adults
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Pediatrics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Global Rivaroxaban Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Introduction
  - Market Share Analysis, 2026 and 2033 (%)
  - Y-o-Y Growth Analysis, 2021 - 2033
  - Segment Trends
- Hospitals and Clinics
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Global Rivaroxaban Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
  - Market Share (%) Analysis, 2026,2028 & 2033, Value (USD Mn)
  - Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Mn)
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    - Brazil
    - Argentina
    - Mexico
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    - Germany
    - U.K.
    - Spain
    - France
    - Italy
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    - GCC Countries
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Mn)
  - Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
    - South Africa
    - North Africa
    - Central Africa
COMPETITIVE LANDSCAPE
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Janssen Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Interquim SA
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Natco Pharma
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Mylan N.V.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sandoz (a Novartis division)
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Aurobindo Pharma
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Zydus Cadila
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Apotex Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Hetero Labs Limited
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Fresenius Kabi AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Lupin Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Reddy's Laboratories
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Bristol-Myers Squibb
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Eisai Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
References and Research Methodology
- References
- Research Methodology
- About us

*Browse 32 market data tables and 28 figures on 'Global Rivaroxaban Market' - Global forecast to 2033

Get Instant Access - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now